- 18/4/2020 - 31/12/2021
- Technische Universität München
- EIT Health
The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.
Altres projectesVeure projectes passats
Combatent la Resistència Bacteriana a Europa
Eradicació del Pian
Application to medical devices
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Prioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
Integrating and decentralizing diabetes and hypertension services in Africa
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
Estudio piloto para evaluar el potencial de la ivermectina para reducir la transmisión de COVID-19
Cendea de Cizur
Conèixer la propagació. Entendre la protecció
A breakthrough device for the rapid detection of antimicrobial resistance
Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19
Hepatitis B Virus COMmunity Screening and Vaccination in Africans
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV
Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.
Close the Gap, Increase Access, Provide Adequate Therapy
Strengthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19
Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia
Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status
Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring
Las ciudades y la salud
ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)